Volume 90, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Several risk groups are known for the rare but serious, frequently fatal, viscerotropic reactions following live yellow fever virus vaccine (YEL-AVD). Establishing additional risk groups is hampered by ignorance of the numbers of vaccinees in factor-specific risk groups thus preventing their use as denominators in odds ratios (ORs). Here, we use an equation to calculate ORs using the prevalence of the factor-specific risk group in the population who remain well. The 95% confidence limits and values can also be calculated. Moreover, if the estimate of the prevalence is imprecise, discrimination analysis can indicate the prevalence at which the confidence interval results in an OR of ∼1 revealing if the prevalence might be higher without yielding a non-significant result. These methods confirm some potential risk groups for YEL-AVD and cast doubt on another. They should prove useful in situations in which factor-specific risk group denominator data are not available.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Monath TP, Gershman M, Staples JE, Barrett AD, Plotkin SA, Orenstein WA, Offit PA, , 2012. Yellow fever vaccine. , eds. Vaccines. Sixth edition. China: Saunders, 870968. [Google Scholar]
  2. Monath TP, , 2012. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 11: 427448.[Crossref] [Google Scholar]
  3. Barwick R, , 2004. History of thymoma and yellow fever vaccination. Lancet 364: 936.[Crossref] [Google Scholar]
  4. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB, , 2008. Adverse event reports following yellow fever vaccination. Vaccine 26: 60776082.[Crossref] [Google Scholar]
  5. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS, , 2005. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23: 32563263.[Crossref] [Google Scholar]
  6. Seligman SJ, , 2011. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis 17: 18911893.[Crossref] [Google Scholar]
  7. Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Bastos Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins RD, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS, , 2012. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 30: 50385058.[Crossref] [Google Scholar]
  8. Isenman H, Burns A, , 2012. A case of yellow fever vaccine-associated disease. NZ Med J 125: 9295. [Google Scholar]
  9. Breugelmans JG, Lewis RF, Agbenu E, Veit O, Jackson D, Domingo C, Bothe M, Perea W, Niedrig M, Gessner BD, Yactayo S, , 2013. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 31: 18191829.[Crossref] [Google Scholar]
  10. Altman DG, Bland JM, , 2011. How to obtain the P value from a confidence interval. BMJ 343: d2304.[Crossref] [Google Scholar]
  11. Casanova JL, Abel L, , 2009. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 206: 18391843.[Crossref] [Google Scholar]
  12. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, Glidewell J, Monson N, Zhu T, Zhu H, Staprans S, Lee D, Brinton MA, Perelygin AA, Vellozzi C, Brachman P, Jr Lalor S, Teuwen D, Eidex RB, Cetron M, Priddy F, del Rio C, Altman J, Ahmed R, , 2008. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198: 500507.[Crossref] [Google Scholar]
  13. Casanova JL, Jouanguy E, Lamhamedi S, Blanche S, Fischer A, , 1995. Immunological conditions of children with BCG disseminated infection. Lancet 346: 581.[Crossref] [Google Scholar]
  14. Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL, , 2010. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann N Y Acad Sci 1214: 1833.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 19 Sep 2013
  • Accepted : 09 Nov 2013
  • Published online : 05 Feb 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error